SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

iTeos Therapeutics, Inc.

(Name of Issuer)

Common stock, par value $0.001 per share

(Title of Class of Securities)

46565G104

(CUSIP Number)

07/21/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

46565G104

Names of Reporting Persons

Ridgeback Capital Investments L.P.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,942,959.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,942,959.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,942,959.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.1 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: The percentages used herein are calculated based upon 38,273,795 shares of common stock outstanding as of April 22, 2025, as reported by the Company in its Quarterly Report on Form 10-Q filed with the SEC on April 28, 2025.

SCHEDULE 13G

CUSIP No.

46565G104

Names of Reporting Persons

Ridgeback Capital Investments LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,942,959.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,942,959.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,942,959.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.1 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

CUSIP No.

46565G104

Names of Reporting Persons

Ridgeback Capital Management LLC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,942,959.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,942,959.00

Aggregate Amount Beneficially Owned by Each Reporting Person

1,942,959.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

5.1 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

iTeos Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

321 Arsenal Street Bldg. 312, Floor 3, Suite 301, Watertown, MA, 02472

Item 2.

(a)

Name of person filing:

This statement is filed on behalf of the following persons with respect to shares of common stock of the Company acquired by them (the "Shares"): (i)Ridgeback Capital Investments L.P., Delaware limited partnership ("RCILP"), with respect to Shares beneficially owned by it; (ii)Ridgeback Capital Investments LLC, a Delaware limited liability company ("RCI"), with respect to Shares beneficially owned by it; and (iii)Ridgeback Capital Management LLC, a Delaware limited liability company ("RCM"), with respect to Shares beneficially owned by it. The foregoing persons are hereinafter referred to collectively as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. RCM and RCI do not own any Shares directly. RCI is the general partner of RCILP. Pursuant to an investment management agreement, RCM maintains investment and voting power with respect to the securities held or controlled by RCI. Wayne Holman, an individual, controls RCM. By reason of the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, RCM and RCI may be deemed to own beneficially all of the Shares (constituting approximately 5.1% of the shares outstanding). Each of RCM and RCI disclaim beneficial ownership of any of the securities covered by this statement, except to the extent of any pecuniary interest therein.

(b)

Address or principal business office or, if none, residence:

30 Star Island Drive, Miami, FL, 33139

(c)

Citizenship:

RCILP is a Delaware limited partnership. RCI is a Delaware limited liability company. RCM is a Delaware limited liability company.

(d)

Title of class of securities:

Common stock, par value $0.001 per share

(e)

CUSIP No.:

46565G104

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

Ridgeback Capital Investments L.P.: 1,942,959 Ridgeback Capital Investments LLC: 1,942,959 Ridgeback Capital Management LLC: 1,942,959

(b)

Percent of class:

Ridgeback Capital Investments L.P.: 5.1% Ridgeback Capital Investments LLC: 5.1% Ridgeback Capital Management LLC: 5.1%

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Ridgeback Capital Investments L.P.: -0- Ridgeback Capital Investments LLC: -0- Ridgeback Capital Management LLC: -0-

(ii) Shared power to vote or to direct the vote:

Ridgeback Capital Investments L.P.: 1,942,959 Ridgeback Capital Investments LLC: 1,942,959 Ridgeback Capital Management LLC: 1,942,959

(iii) Sole power to dispose or to direct the disposition of:

Ridgeback Capital Investments L.P.: -0- Ridgeback Capital Investments LLC: -0- Ridgeback Capital Management LLC: -0-

(iv) Shared power to dispose or to direct the disposition of:

Ridgeback Capital Investments L.P.: 1,942,959 Ridgeback Capital Investments LLC: 1,942,959 Ridgeback Capital Management LLC: 1,942,959

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ridgeback Capital Investments L.P.

Signature:	/s/ Nicole Venezia
Name/Title:	Nicole Venezia/General Counsel
Date:	07/25/2025

Ridgeback Capital Investments LLC

Signature:	/s/ Nicole Venezia
Name/Title:	Nicole Venezia/General Counsel
Date:	07/25/2025

Ridgeback Capital Management LLC

Signature:	/s/ Nicole Venezia
Name/Title:	Nicole Venezia/General Counsel
Date:	07/25/2025

Exhibit Information

Exhibit Number 99.1 - Joint Filing Agreement

SEC Form SCHEDULE 13G filed by iTeos Therapeutics Inc.